U.S. Court in DC Says CMS Arbitrarily Denied Drug Maker Phase-In Status for Part D Discounts
- October 10, 2025
The U.S. District Court for the District of Columbia sided with PharmEssentia USA in its challenge to the Centers for Medicare & Medicaid Services’ (CMS’) decision to deny the drug maker a special status allowing the drug maker to gradually phase in drug discounts under the Inflation Reduction Act (IRA).
ARTICLE TAGS
You must be logged in to access this content.